Literature DB >> 12759245

Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries.

Napoleone Ferrara1, Gretchen Frantz, Jennifer LeCouter, Lisa Dillard-Telm, Thinh Pham, Aparna Draksharapu, Thomas Giordano, Franklin Peale.   

Abstract

Angiogenesis is a key aspect of the dynamic changes occurring during the normal ovarian cycle. Hyperplasia and hypervascularity of the ovarian theca interna and stroma are also prominent features of the polycystic ovary syndrome (PCOS), a leading cause of infertility. Compelling evidence indicated that vascular endothelial growth factor (VEGF) is a key mediator of the cyclical corpus luteum angiogenesis. However, the nature of the factor(s) that mediate angiogenesis in PCOS is less clearly understood. Endocrine gland-derived (EG)-VEGF has been recently identified as an endothelial cell mitogen with selectivity for the endothelium of steroidogenic glands and is expressed in normal human ovaries. In the present study, we compared the expression of EG-VEGF and VEGF mRNA in a series of 13 human PCOS and 13 normal ovary specimens by in situ hybridization. EG-VEGF expression in normal ovaries is dynamic and generally complementary to VEGF expression in both follicles and corpora lutea. A particularly high expression of EG-VEGF was detected in the Leydig-like hilus cells found in the highly vascularized ovarian hilus. In PCOS ovaries, we found strong expression of EG-VEGF mRNA in theca interna and stroma in most of the specimens examined, thus spatially related to the new blood vessels. In contrast, VEGF mRNA expression was most consistently associated with the granulosa cell layer and sometimes the theca, but rarely with the stroma. These findings indicate that both EG-VEGF and VEGF are expressed in PCOS ovaries, but in different cell types at different stages of differentiation, thus suggesting complementary functions for the two factors in angiogenesis and possibly cyst formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759245      PMCID: PMC1868136          DOI: 10.1016/S0002-9440(10)64322-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  The polycystic ovary. I. Clinical and histologic features.

Authors:  J W GOLDZIEHER; J A GREEN
Journal:  J Clin Endocrinol Metab       Date:  1962-03       Impact factor: 5.958

2.  Vascular endothelial growth factor is expressed in rat corpus luteum.

Authors:  H S Phillips; J Hains; D W Leung; N Ferrara
Journal:  Endocrinology       Date:  1990-08       Impact factor: 4.736

3.  The role of lipoproteins in the regulation of progesterone secretion by the human corpus luteum.

Authors:  B R Carr; P C MacDonald; E R Simpson
Journal:  Fertil Steril       Date:  1982-09       Impact factor: 7.329

Review 4.  Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.

Authors:  A M Ryan; D B Eppler; K E Hagler; R H Bruner; P J Thomford; R L Hall; G M Shopp; C A O'Neill
Journal:  Toxicol Pathol       Date:  1999 Jan-Feb       Impact factor: 1.902

5.  Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary.

Authors:  S Yamamoto; I Konishi; Y Tsuruta; K Nanbu; M Mandai; H Kuroda; K Matsushita; A A Hamid; Y Yura; T Mori
Journal:  Gynecol Endocrinol       Date:  1997-12       Impact factor: 2.260

6.  Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary.

Authors:  N Ravindranath; L Little-Ihrig; H S Phillips; N Ferrara; A J Zeleznik
Journal:  Endocrinology       Date:  1992-07       Impact factor: 4.736

7.  Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor.

Authors:  H M Fraser; S E Dickson; S F Lunn; C Wulff; K D Morris; V A Carroll; R Bicknell
Journal:  Endocrinology       Date:  2000-03       Impact factor: 4.736

8.  The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome.

Authors:  H Kobayashi; Y Okada; T Asahina; J Gotoh; T Terao
Journal:  J Mol Endocrinol       Date:  1998-06       Impact factor: 5.098

9.  Snake venom. The amino acid sequence of protein A from Dendroaspis polylepis polylepis (black mamba) venom.

Authors:  F J Joubert; D J Strydom
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1980-12

10.  Gonadotropin-binding sites in the rhesus monkey ovary: role of the vasculature in the selective distribution of human chorionic gonadotropin to the preovulatory follicle.

Authors:  A J Zeleznik; H M Schuler; L E Reichert
Journal:  Endocrinology       Date:  1981-08       Impact factor: 4.736

View more
  50 in total

1.  VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Authors:  Jianying Dong; Jeremy Grunstein; Max Tejada; Frank Peale; Gretchen Frantz; Wei-Ching Liang; Wei Bai; Lanlan Yu; Joe Kowalski; Xiaohuan Liang; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

Review 2.  The prokineticins: a novel pair of regulatory peptides.

Authors:  Qun-Yong Zhou
Journal:  Mol Interv       Date:  2006-12

3.  Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels.

Authors:  Stephanie Debette; Sophie Visvikis-Siest; Ming-Huen Chen; Ndeye-Coumba Ndiaye; Ci Song; Anita Destefano; Radwan Safa; Mohsen Azimi Nezhad; Douglas Sawyer; Jean-Brice Marteau; Vanessa Xanthakis; Gerard Siest; Lisa Sullivan; Michele Pfister; Holly Smith; Seung-Hoan Choi; John Lamont; Lars Lind; Qiong Yang; Peter Fitzgerald; Erik Ingelsson; Ramachandran S Vasan; Sudha Seshadri
Journal:  Circ Res       Date:  2011-07-14       Impact factor: 17.367

Review 4.  Novel therapies targeting endometriosis.

Authors:  Hugh S Taylor; Kevin G Osteen; Kaylon L Bruner-Tran; Charles J Lockwood; Graciela Krikun; Anna Sokalska; Antoni J Duleba
Journal:  Reprod Sci       Date:  2011-06-21       Impact factor: 3.060

Review 5.  The prokineticin system: an interface between neural inflammation and pain.

Authors:  Silvia Franchi; Paola Sacerdote; Alberto Panerai
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

Review 6.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

Review 7.  Targeting the tumour vasculature: insights from physiological angiogenesis.

Authors:  Alicia S Chung; John Lee; Napoleone Ferrara
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

Review 8.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

9.  Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine.

Authors:  J J Petrik; H C Gerstein; C E Cesta; L D Kellenberger; N Alfaidy; A C Holloway
Journal:  Endocrine       Date:  2009-08-20       Impact factor: 3.633

10.  Association between ACE gene I/D polymorphisms and hyperandrogenism in women with polycystic ovary syndrome (PCOS) and controls.

Authors:  Jing Sun; Haijian Fan; Yena Che; Yunxia Cao; Xiaoke Wu; Hai-xiang Sun; Fengjing Liang; Long Yi; Yong Wang
Journal:  BMC Med Genet       Date:  2009-07-14       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.